



FDA's New Neuroscience Initiative Seeks to Foster Innovation, Accelerate Alzheimer's Prevention

October 28, 2026

Reading Time : **1 min**

By: Anna K. Abram, Nathan A. Brown, Mara LeFevre

On October 22, 2026, the Food and Drug Administration (FDA) announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency-wide initiative focused on advancing medical product development for diseases and conditions affecting the brain and nervous system. The program seeks to advance the scientific tools and regulatory approaches in neuroscience product development to foster innovation on behalf of patients.

Developing medical products for neuroscience indications can present distinct scientific and clinical challenges and this new initiative seeks to harness cross-center collaboration across FDA's Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health to advance product development and foster innovation in these areas of product development. In announcing NAIN, the agency acknowledged these development challenges as well as the opportunities scientific advances, such as in biomarkers and digital health technologies, present to inform medical product development and advance innovation. NAIN's inaugural initiative, the Alzheimer's Prevention Accelerator, seeks to advance the science, tools and regulatory approaches needed to support the development of medical products intended to prevent or delay the onset or progression of cognitive decline due to Alzheimer's disease—a devastating condition affecting millions of Americans, their families and caregivers.

A key aspect of NAIN is engagement with patients, industry and other stakeholders on cross-cutting neuroscience topics encompassing drug, biologics and devices, for the diagnosis,

treatment and prevention of conditions affecting the brain and nervous system, including neurologic and psychiatric disorders, mental health conditions, addiction and pain. Given NAIN's broad scope and ambitious goals, patient advocates and policy-makers on Capitol Hill are likely to be interested in how this new program unfolds and it may emerge as one of the topics Congress engages on in the context of the upcoming medical product user fee reauthorizations and broader bipartisan dialogue on the challenges and opportunities in advancing medical product development for American patients.

Categories

Medical Devices

Policy

Food and Drug Administration (FDA)

Healthcare Innovations

[Subscribe to the Eye on FDA Blog Series >](#)

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and

other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.